New combo therapy shows promise for shrinking lung tumors before surgery
NCT ID NCT06293690
First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 21 times
Summary
This study tests whether combining the immunotherapy drug toripalimab with targeted radiation (SBRT) before surgery can shrink tumors in people with stage IIA to IIIB non-small cell lung cancer. About 40 adults aged 18-75 who are eligible for surgery will receive the treatment. The goal is to see if this approach leads to major or complete tumor disappearance at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.